Pilar
Font Ugalde
Publicaciones en las que colabora con Pilar Font Ugalde (3)
2023
-
Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain
International Journal of Dermatology, Vol. 62, Núm. 5, pp. 700-706
2022
-
Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines
Life, Vol. 12, Núm. 11
-
Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)
Journal of Clinical Medicine, Vol. 11, Núm. 17